Ibrutinib Monotherapy Looks Good in Patients with CLL or SLL

Janssen Pharmaceutical has presented positive data from its RESONATE trial of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

The data is being presented in full on June 3 at the American Society of Clinical Oncology (ASCO) meeting in Chicago and simultaneously published in a special edition of The New England Journal of Medicine.

RESONATE

RESONATE is an international, multicenter Phase 3 trial in 391 patients with relapsed or refractory CLL or SLL. Patients received either oral ibrutinib once daily, or ofatumumab administered intravenously.

Monotherapy ibrutinib was found to significantly lengthen progression-free survival (PFS) and overall survival (OS) compared with ofatumumab.

Ibrutinib is an investigational compound within a class of medicines called Bruton's tyrosine kinase (BTK) inhibitors.

PFS was the primary endpoint of the RESONATE study, with OS, overall response rate (ORR) and safety as key secondary endpoints.

The results demonstrated the superiority of ibrutinib monotherapy in this patient population which is notoriously difficult-to-treat, and it did so regardless of baseline disease characteristics.

Specifically, 43 percent of ibrutinib patients achieved a partial response (PR) compared to only four percent of patients taking ofatumumab.

"These results add to the body of clinical data demonstrating the value of ibrutinib in previously treated CLL patients," said Jane Griffiths, Company Group Chairman of Janssen Europe, the Middle East and Africa (EMEA). "These are the first Phase 3 data for ibrutinib. We're pleased to see the strong hazard ratios for progression-free and overall survival and are encouraged that many patients continue to do well on treatment with ibrutinib."

Source: PR Newswire

More Articles

More Articles

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

Canine lymphoma, just like lymphoma in humans, can be separated into stages,...